Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 670,097 shares of the biopharmaceutical company’s stock after acquiring an additional 4,540 shares during the period. Migdal Insurance & Financial Holdings Ltd.’s holdings in Pfizer were worth $23,922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also modified their holdings of the company. Shine Investment Advisory Services Inc. purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $102,000. Mckinley Capital Management LLC Delaware purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $103,000. D. Scott Neal Inc. raised its position in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the last quarter. Herndon Capital Management LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $120,000. Finally, Private Vista LLC raised its position in shares of Pfizer by 2,277.3% in the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 190,933 shares during the last quarter. Institutional investors own 70.06% of the company’s stock.
Several equities analysts recently weighed in on the stock. SunTrust Banks reiterated a “hold” rating and issued a $40.00 price target (up previously from $33.00) on shares of Pfizer in a report on Monday, January 29th. BMO Capital Markets reiterated a “buy” rating and issued a $39.00 price target on shares of Pfizer in a report on Friday, November 10th. Jefferies Group set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Thursday, October 26th. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective on the stock in a research note on Monday, January 8th. Finally, Berenberg Bank set a $36.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, October 31st. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $39.45.
In related news, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. 0.06% of the stock is owned by insiders.
Shares of Pfizer Inc. (NYSE:PFE) traded up $0.25 during mid-day trading on Wednesday, reaching $35.19. The company’s stock had a trading volume of 23,217,653 shares, compared to its average volume of 26,760,000. Pfizer Inc. has a 12 month low of $31.67 and a 12 month high of $39.43. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The stock has a market cap of $209,760.00, a price-to-earnings ratio of 10.00, a P/E/G ratio of 1.96 and a beta of 0.94.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. During the same quarter in the previous year, the firm earned $0.47 EPS. The company’s quarterly revenue was up .6% compared to the same quarter last year. equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.86%. The ex-dividend date is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is currently 38.64%.
Pfizer announced that its Board of Directors has initiated a stock repurchase plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/14/migdal-insurance-financial-holdings-ltd-has-23-92-million-position-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.